Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More Danes opt for private sector treatment:

This article was originally published in Clinica

Executive Summary

The extension of the Danish law on free hospital selection saw some 900 patients opt for treatment in the private sector and a further 25 seek treatment abroad between July 1 and August 10 2002. The updated version of the law came into force on July 1 and applied to patients who were forced to wait for treatment paid for by their own county council for more than two months in the public sector. "At present we have entered into talks with 55 hospitals and clinics in total, but we are continuing to initiate new talks," said Kristian Ebbensgaard, chairman of the Danish association of county councils. The association stressed, however, that this trend was in no way alarming. During this 40-day period, some 100,000 patients were discharged from public sector hospitals.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT067932

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel